ArticleBioMed research international2020
Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Centrosomal protein 72 deficiency exacerbates liver fibrosis induced by Schistosoma japonicum infection.Parasites & vectors · 2026Article
- DamageZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- CEP55 promotes prostate cancer progression via TPX2-dependent activation of AURKA-PI3K-AKT signaling and inhibition of ferroptosis.The Journal of biological chemistry · 2026Article
- Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma.Frontiers in immunology · 2025Article
- CEP55: Implications for Immunotherapy and Survival in Hepatocellular Carcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- Cancer/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients.PloS one · 2025Article
- CEP55 Promotes Acral Melanoma Progression via MAPK Pathway and Predicts Survival Following Immunotherapy.Oncology research · 2025Article
- Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.Cell death & disease · 2024Review
- G6PD and machine learning algorithms as prognostic and diagnostic indicators of liver hepatocellular carcinoma.BMC cancer · 2024Article
- Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer.Vaccines · 2024Article
- Role and therapeutic potential of E3s in the tumor microenvironment of hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Article
- Hsa-miR-195-5p Inhibits Autophagy and Gemcitabine Resistance of Lung Adenocarcinoma Cells via E2F7/CEP55.Biochemical genetics · 2023Article
- Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma.BMC medical genomics · 2023Article
- CEP55: an immune-related predictive and prognostic molecular biomarker for multiple cancers.BMC pulmonary medicine · 2023Article
- A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target.Diagnostics (Basel, Switzerland) · 2023Article
- Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer.Frontiers in molecular biosciences · 2023Article
- Circ_0136666 aggravates osteosarcoma development through mediating miR-1244/CEP55 axis.Journal of orthopaedic surgery and research · 2022Article
- Correlation analysis of intestinal flora and immune function in patients with primary hepatocellular carcinoma.Journal of gastrointestinal oncology · 2022Article
- Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was performed to investigate the association of CEP55 expression with liver cancer and explore potential underlying mechanisms.
resultsCEP55 was significantly overexpressed in the liver tumor sample compared to the adjacent normal liver sample. High CEP55 expression was significantly associated with histological grade, advanced stages, histological type, high T classification, and survival status. High CEP55 expression was significantly related to dismal prognosis compared with low CEP55 expression, which was validated by the GSE54236 dataset and ICGC database. Meanwhile, CEP55 was identified as the risk factor to independently predict overall survival (OS) for patients with liver cancer upon multivariate analysis. Enrichment analysis indicated that cell cycle, DNA replication, pathways in cancer, mTOR signaling pathway, and VEGF signaling pathway were significantly enriched in the high CEP55 expression group. In addition, the CEP55 expression was significantly related to the infiltration level of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells in hepatocellular carcinoma (HCC). CEP55 methylation level was negatively correlated to its mRNA expression. And patients with CEP55 hypermethylation and low expression can achieve a better prognosis than those with CEP55 hypomethylation and high expression.
conclusionCEP55 may serve as a candidate treatment target for it is a determinant of prognosis and immune infiltration in liver cancer patients. DNA hypomethylation might contribute to the overexpression of CEP55 in liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.